Compare HSII & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HSII | ARDX |
|---|---|---|
| Founded | 1953 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.5B |
| IPO Year | 1999 | 2014 |
| Metric | HSII | ARDX |
|---|---|---|
| Price | $59.01 | $6.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $57.50 | $10.65 |
| AVG Volume (30 Days) | 430.9K | ★ 2.7M |
| Earning Date | 11-03-2025 | 10-30-2025 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.73 | N/A |
| Revenue | ★ $1,199,854,000.00 | $398,234,000.00 |
| Revenue This Year | $13.60 | $22.71 |
| Revenue Next Year | N/A | $27.81 |
| P/E Ratio | $34.12 | ★ N/A |
| Revenue Growth | 11.56 | ★ 58.12 |
| 52 Week Low | $36.87 | $3.21 |
| 52 Week High | $59.05 | $6.78 |
| Indicator | HSII | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 77.94 | 62.17 |
| Support Level | $58.84 | $5.77 |
| Resistance Level | $59.05 | $6.20 |
| Average True Range (ATR) | 0.09 | 0.27 |
| MACD | -0.11 | 0.03 |
| Stochastic Oscillator | 89.74 | 91.30 |
Heidrick & Struggles International Inc is a leadership advisory firm providing executive search and consulting services to businesses and business leaders world wide. The company's operating segments include the executive search business which operates in the Americas; Europe; Asia Pacific and On-Demand Talent and Heidrick Consulting. It generates maximum revenue from the Americas.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.